A revision of the organ radiation doses from 2-fluoro-2-deoxy-d-glucose with reference to tumour presence

Radiation Protection Dosimetry

Volumn 151, Issue 1, 2012, Pages 43-50

  Staaf, Johan ^a,b   Jacobsson, Hans ^b   Sanchez Crespo, Alejandro ^b  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; IMAGE QUALITY; LUNG TUMOR; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION PROTECTION; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIATION PROTECTION; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE BODY IMAGING;

EID: 84864928778     PISSN: 01448420     EISSN: 17423406     Source Type: Journal    
DOI: 10.1093/rpd/ncr471     Document Type: Article

References (16)

1. Cristy, M. and Eckerman, K. F. Specific absorbed fractions of energy at various ages from internal photon sources. ORNL/TM-8381 V1-V7. Oak ridge National Laboratory (1987).
2. ICRP. Radiation dose to patients from radiapharmaceuticals. ICRP Publication 106. Elsevier (2008).
3. Hays, M. T., Watson, E., Thomas, S. and Stabin, M. MIRD dose estimate report no. 19: radiation absorbed dose estimates from 18F-FDG. J. Nucl. Med. 43, 210-214 (2002).
4. Snyder, W. S., Ford, M. R., Warner, G. G. and Watson, S. B. 'S' absorbed dose per cumulated activity for selected radionuclides and organs (MIRD pamphlet no. 11). Society of Nuclear Medicine (1975).
5. Schmidt, K. and Turkeheimer, F. Kinetic modeling in positron emission tomography. Q. J. Nucl. Med. 46, 70-85 (2002).
6. Haberkorn, U., Strauss, L. G., Reisser, C., Haag, D., Dimitrakopoulou, A., Ziegler, S., Oberdorfer, F., Rudat, V. and van Kaick, G. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J. Nucl. Med. 32, 1548-1555 (1991).
7. Haberkorn, U., Strauss, L. G., Dimitrakopoulou, A., Seiffert, E., Oberdorfer, F., Ziegler, S., Reisser, C., Doll, J., Helus, F. and van Kaick, G. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med. 34, 12-17 (1993).
8. Deloar, H. M., Fujiwara, T., Shidahara, M., Nakamura, T., Watabe, H., Narita, Y., Itoh, M., Miyake, M. and Watanuki, S. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using wholebody positron emission tomography and magnetic resonance imaging. Eur. J. Nucl. Med. 25, 565-574 (1998).
9. Mejia, A. A., Nakamura, T., Masatoshi, I., Hatazawa, J., Masaki, M. and Watanuki, S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J. Nucl. Med. 32, 699-706 (1991).
10. Marieb, E. and Hoehn, K. Human Anatomy & Physiology, seventh edn. Pearson Benjamin Cummings, p. 317 (2007). ISBN: 0805353879.
11. Engel, H., Steinert, H., Buck, A., Berthold, T., Huch Böni, R. A. and von Schulthess, G. K. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J. Nucl.Med. 37, 441-446 (1996).
12. Loevinger, R., Budinger, T. F. and Watson, E. E. MIRD primer for absorbed dose calculations. The Society of Nuclear Medicine, Inc. (1988).
13. Thomas, S. R., Stabin, M. G., Chen, C.-T. and Samaratunga, R. C. MIRD pamphlet no. 14 revised: a dynamic urinary bladder model for radiation dose calculations. J. Nucl. Med. 40, 102S-123S (1999).
14. Stabin, M. G. and Siegel, J. A. Physical models and dose factors for use in internal dose assessment. Health Phys. 85(3), 294-310 (2003).
15. Basu, S., Kung, J., Houseni, M., Zhuang, H., Tidmarsh, G.F. and Alavi, A. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinom: implications for its utilization in assessing malignant lesions. Q. J. Nucl. Med. Mol. Imaging 53, 9-16 (2009).
16. Okazumi, S., Isono, K., Enomoto, K., Kikuchi, T., Ozaki, M., Yamamoto, H., Hayashi, H., Asano, T. and Ryu, M. Evaluation of liver tumors using flourine-18 fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J. Nucl. Med. 33, 333-339 (1992).